FIU Discovery

The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer

Mortality Trends for Lung Cancer and Smoking Prevalence In Peru.  ASIAN PACIFIC JOURNAL OF CANCER PREVENTION.  23:435-443.

EGFR L718V (+)/T790M (-) as a Mechanism of Resistance in Patients with Metastatic Non-small-cell Lung Cancer with EGFR L858R Mutations

Influence of Sex in the Molecular Characteristics and Outcomes of Malignant Tumors

Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)

Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)

Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease

Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.  CLINICAL CANCER RESEARCH.  27:1019-1028.

Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors

Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey

Scientific publications in cancer: in Latin America, strong scientific networks increase productivity (the TENJIN study).  JOURNAL OF CLINICAL EPIDEMIOLOGY.  126:1-8.

Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.  EXPERT REVIEW OF RESPIRATORY MEDICINE.  14:385-390.

Complete Response of Primary Refractory ALK-Positive Large B-Cell Lymphoma Treated With Single-Agent Nivolumab

Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards.  JOURNAL OF CLINICAL ONCOLOGY.  38:633-+.

Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).  THORACIC CANCER.  11:353-361.

Lung Cancer in the Young.  LUNG.  198:195-200.

Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer.  EXPERT OPINION ON BIOLOGICAL THERAPY.  19:509-515.

Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients

Molecular Epidemiology of ALK Rearrangements in Advanced Lung Adenocarcinoma in Latin America.  ONCOLOGY.  96:207-216.

Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.  CANCER RESEARCH.  79:625-638.

Exosome-Based Detection of EGFR T790M in Plasma from Non-Small Cell Lung Cancer Patients.  CLINICAL CANCER RESEARCH.  24:2944-2950.

Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types.  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS.  500:621-625.

Making Sense of Immunotherapy in Lung Cancer: What the Pulmonologist Needs to Know?

Gender and outcomes in non-small cell lung cancer: An old prognostic variable comes back for targeted therapy and immunotherapy?

Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.  NEW ENGLAND JOURNAL OF MEDICINE.  378:731-739.

Ceritinib: an orphan drug for ALK positive non-small cell lung cancer with robust clinical evidence

In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib

The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche.  CANCER LETTERS.  402:43-51.

Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America

Checkpoints inhibitors in first line therapy of metastatic non-small cell lung cancer patients.  TRANSLATIONAL CANCER RESEARCH.  5:S1443-S1448.

3PD Liquid biopsy in patients with adenocarcinoma of the lung and its correlation with their tumor tissue molecular profile.  JOURNAL OF THORACIC ONCOLOGY.  11:S58.

Missed clinical benefit due to false negatives in testing for EGFR T790M mutations in non-small cell lung cancer

Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.  EXPERT OPINION ON INVESTIGATIONAL DRUGS.  24:1101-1109.

Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines.  CURRENT ONCOLOGY REPORTS.  16.

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.  JOURNAL OF CLINICAL ONCOLOGY.  32:2735-2743.

The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFR-Inhibitors: Did We Really Find the Target?.  CURRENT DRUG TARGETS.  15:1284-1292.

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer

BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.  EXPERT OPINION ON INVESTIGATIONAL DRUGS.  22:1081-1088.

Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.  CANCER BIOLOGY & THERAPY.  14:557-563.

Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase ii trial.  JOURNAL OF CLINICAL ONCOLOGY.  31:1415-1421.

A phase i dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors.  CANCER CHEMOTHERAPY AND PHARMACOLOGY.  71:523-530.

A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).  CANCER CHEMOTHERAPY AND PHARMACOLOGY.  72:1103-1110.

A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors.  CANCER.  118:4262-4270.

Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck

Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.  JOURNAL OF CLINICAL ONCOLOGY.  29:1140-1145.

A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum-and erlotinib-resistant adenocarcinoma of the lung.  JOURNAL OF THORACIC ONCOLOGY.  5:1054-1059.

Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.  JOURNAL OF THORACIC ONCOLOGY.  5:533-539.

Developing a vaccine for non-small-cell lung cancer

Radiation technique influence on percutaneous endoscopic gastrostomy tube dependence: Comparison between two radiation schemes.  HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK.  31:944-948.

Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: Survival, surgery, and organ preservation

Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer.  JOURNAL OF THORACIC ONCOLOGY.  3:511-515.

Intensity-Modulated Radiotherapy With Concurrent Chemotherapy for Previously Irradiated, Recurrent Head and Neck Cancer.  INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS.  69:1067-1073.

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.  NEW ENGLAND JOURNAL OF MEDICINE.  357:1705-1715.

Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.  JOURNAL OF CLINICAL ONCOLOGY.  24:5025-5033.

Advantage of EUS Trucut biopsy combined with fine-needle aspiration without immediate on-site cytopathologic examination.  GASTROINTESTINAL ENDOSCOPY.  64:505-511.

Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC)

Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: Case report and review of literature

Pemetrexed-associated urticarial vasculitis

The utility of a bone marrow biopsy in diagnosing the source of fever of unknown origin in patients with AIDS.  JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES.  37:1599-1603.

Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.  JOURNAL OF CLINICAL ONCOLOGY.  22:2800-2807.

Induction of CD8 T-cell-Ifn-γ response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma

Primary Hepatic Non-Hodgkin's Lymphomas: Case Report and Review of the Literature.  AMERICAN JOURNAL OF GASTROENTEROLOGY.  98:2789-2793.

Survival of renal allograft following de novo hemolytic uremic syndrome after kidney transplantation.  TRANSPLANTATION PROCEEDINGS.  35:1370-1374.

Radical resection of periampullary tumors in the elderly: Evaluation of long-term results

Post-liver transplantation lymphoproliferative disorders with and without infusions of donor bone marrow cells

Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2.  AIDS RESEARCH AND HUMAN RETROVIRUSES.  15:713-719.

Pulmonary bone marrow embolism in sickle cell disease.  SOUTHERN MEDICAL JOURNAL.  92:245-247.

Is central nervous system prophylaxis necessary in ocular adnexal lymphoma?

Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL)

Successful treatment of lymphomatoid granulomatosis using Cyclosporin-A after failure of intensive chemotherapy

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.  MOLECULAR CANCER THERAPEUTICS. 2577-2584.

"Real World" Use of Liquid Biopsy in Patients With Lung Adenocarcinoma and Correlation With Tumor Tissue Genetic Profile.  JOURNAL OF THORACIC ONCOLOGY. S199-S200.

Lung Cancer Chromosomal Aberrations and Gene Expression Profiles of Hispanics Living in the US or Latin America are Similar.  JOURNAL OF THORACIC ONCOLOGY. S187-S188.

Lung Cancer Chromosomal Aberrations and Gene Expression Profiles of Hispanics Living in the US or Latin America are Similar.  JOURNAL OF THORACIC ONCOLOGY. S176-S176.

Genomic Analysis of Lung Cancer Tumors from Hispanic Patients Living in the US.  JOURNAL OF THORACIC ONCOLOGY. S232-S232.

EXPLORING DISPARITIES IN HEALTH CARE OUTCOMES IN MINORITY POPULATIONS WITH SMALL (SCLC) AND NON-SMALL CELL LUNG CANCERS (NSCLC).  JOURNAL OF THORACIC ONCOLOGY. S325-S325.

Lung Cancer in Peru.  JOURNAL OF THORACIC ONCOLOGY. 891-898.

Old myths about old patients: The case of non-small cell lung cancer.  TRANSLATIONAL LUNG CANCER RESEARCH. S362-S363.

Cancer vaccines: A new therapeutic alternative for lung cancer therapy?.  727-728.

Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer - Experience from a prematurely closed phase II study [5].  131-132.

Anaphylactic Shock and Cardiac Arrest Secondary to Aprepitant.  AMERICAN JOURNAL OF THERAPEUTICS. E640-E642.

Regarding the Congruence between 2 Circulating Tumor DNA Sequencing Assays.  JAMA ONCOLOGY. 1430.

ROS-1 Rearrangements in Circulating Tumor Cells.  JOURNAL OF THORACIC ONCOLOGY. E71-E72.

EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?.  JOURNAL OF THORACIC ONCOLOGY. e33-e34.

Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.  JOURNAL OF THORACIC ONCOLOGY. e89-e90.

Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer [10].  JOURNAL OF CLINICAL ONCOLOGY. 4244-4245.

Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia [1].  LEUKEMIA & LYMPHOMA. 297-298.

Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB) (vol 151, 102978, 2020).  CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY.

Florida Inter-Specialty Collaborative Project to Improve Cardio-Oncology Awareness and Identify Existing Knowledge Gaps.  JACC: CARDIOONCOLOGY. 535-538.

Lung Cancer Disparities in Hispanics: Molecular Diagnosis and Use of Immunotherapy.  784-788.

Detection of epidermal growth factor receptor mutations in circulating tumor DNA: reviewing BENEFIT clinical trial.  6388-6391.

Tumor Type-Agnostic Treatment and the Future of Cancer Therapy.  TARGETED ONCOLOGY. 541-544.

Moving osimertinib to first-line: the right "strategy" in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?.  S1076-S1080.

Neurotrophic tyrosine kinase gene fusions: another opportunity for targeting in lung cancer.  LUNG CANCER MANAGEMENT. 1-4.

Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer.  EXPERT REVIEW OF MOLECULAR DIAGNOSTICS. 1165-1178.

Neuregulin 1 Gene (NRG1). A Potentially New Targetable Alteration for the Treatment of Lung Cancer

Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?.  EXPERT REVIEW OF ANTICANCER THERAPY. 1229-1235.

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.  RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY. 1647-1662.

Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date.  192-198.

Reaching Across the Aisle: Cardio-Oncology Advocacy and Program Building.  CURRENT ONCOLOGY REPORTS.

Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy.  CANCER DISCOVERY. 1635-1644.

A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation.  TRANSLATIONAL LUNG CANCER RESEARCH. 2113-2119.

Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group.  CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY.

Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB).  CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY.

Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries

The value of immunotherapy in head and neck cancer.  EXPERT OPINION ON BIOLOGICAL THERAPY. 35-43.

Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment.  259-268.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.  JOURNAL OF THORACIC ONCOLOGY. 1248-1268.

The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments.  7-13.

Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression.  TARGETED ONCOLOGY. 175-187.

Challenges in lung cancer screening in Latin America

New targets bring hope in squamous cell lung cancer: Neurotrophic tyrosine kinase gene fusions.  LABORATORY INVESTIGATION. 1268-1270.

Immune checkpoint inhibitors in lung cancer: The holy grail has not yet been found

Second-line treatment of non-small cell lung cancer: Clinical, pathological, and molecular aspects of nintedanib

The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer.  7-12.

Cancer clinical research in Latin America: Current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015

Comprehensive genomic profiling identifies frequent drug-sensitive EGFR exon 19 deletions in NSCLC not identified by prior molecular testing.  CLINICAL CANCER RESEARCH. 3281-3285.

BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?.  CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 32-39.

The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer.  EXPERT OPINION ON INVESTIGATIONAL DRUGS. 385-392.

Entrectinib: A potent new TRK, ROS1, and ALK inhibitor.  EXPERT OPINION ON INVESTIGATIONAL DRUGS. 1493-1500.

Nintedanib in non-small cell lung cancer: From preclinical to approval.  164-172.

cMET in NSCLC: Can we cut off the head of the Hydra? From the pathway to the resistance.  556-573.

Immunotherapy: Is a minor god yet in the pantheon of treatments for lung cancer?.  EXPERT REVIEW OF ANTICANCER THERAPY. 1173-1187.

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.  CANCER TREATMENT REVIEWS. 990-1004.

ALK and crizotinib: after the honeymoon... what else? Resistance mechanisms and new therapies to overcome it.  TRANSLATIONAL LUNG CANCER RESEARCH. 250-261.

Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.  EXPERT OPINION ON BIOLOGICAL THERAPY. 15-26.

Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation.  110-115.

Targeting angiogenesis in non-small-cell lung cancer: A focus on current approaches and future developments.  503-517.

Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer..  1065-1072.

Emerging role of multikinase inhibitors for refractory thyroid cancer.  257-265.

Immunotherapy for nonsmall-cell lung cancer.  90-93.

Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor.  INVESTIGATIONAL NEW DRUGS. 1261-1269.

Novel molecular targeted therapies for refractory thyroid cancer.  HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK. 736-745.

Epidermal growth factor vaccine in non-small-cell lung cancer.  EXPERT REVIEW OF ANTICANCER THERAPY. 439-445.

Targeting the Met pathway in lung cancer.  EXPERT REVIEW OF ANTICANCER THERAPY. 519-528.

Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: Case report and review of literature

Active immunotherapy for non-small-cell lung cancer: Moving toward a reality.  EXPERT REVIEW OF ANTICANCER THERAPY. 1599-1605.

The role of proteasome inhibition in nonsmall cell lung cancer

The role of epidermal growth factor receptor-targeted therapy for squamous cell carcinomas of the head and neck.  25-31.

Development of targeted therapy for squamous cell carcinomas of the head and neck.  EXPERT REVIEW OF ANTICANCER THERAPY. 373-386.

Immunotherapy as a strategy for the treatment of non-small-cell lung cancer.  43-54.

EGF receptor in lung cancer: A successful story of targeted therapy.  EXPERT REVIEW OF ANTICANCER THERAPY. 1577-1587.

Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art.  105-112.

Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC.  EXPERT REVIEW OF ANTICANCER THERAPY. 549-557.

Nasopharyngeal carcinoma: Alternative treatment options after disease progression.  EXPERT REVIEW OF ANTICANCER THERAPY. 377-386.

Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer.  18-24.

Erlotinib (Tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer.  554-564.

How is gene-expression profiling going to challenge the future management of lung cancer?.  827-835.

Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: Present and future.  137-148.

Gene expression profiling and non-small-cell lung cancer: Where are we now?.  168-173.

How important is histology in treatment selection for non small cell lung cancer patients?.  324-331.

Second-line therapy for non-small-cell lung cancer.  91-98.

Controversies in the management of stage IIIA non-small-cell lung cancer.  EXPERT REVIEW OF ANTICANCER THERAPY. 1913-1929.

Targeting important pathways in head and neck cancer: From the bench to the clinic.  EXPERT REVIEW OF ANTICANCER THERAPY. 1819-1835.

Allogeneic tumor-cell-based vaccines secreting endoplasmic reticulum chaperone gp96.  EXPERT OPINION ON BIOLOGICAL THERAPY. 1679-1688.

New targets for non-small-cell lung cancer therapy.  EXPERT REVIEW OF ANTICANCER THERAPY. 1423-1437.

EGFR targeting of solid tumors.  295-304.

Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma.  LEUKEMIA & LYMPHOMA. 2453-2476.

Induction chemotherapy in the management of squamous cell carcinoma of the head and neck.  EXPERT REVIEW OF ANTICANCER THERAPY. 1205-1215.

Present and future of lung cancer vaccines.  445-459.

Heat Shock Protein-Based Cancer Vaccines.  637-659.

New developments in chemotherapy for advanced non-small cell lung cancer.  156-161.

Clinical trials targeting lung cancer with active immunotherapy: The scope of vaccines.  EXPERT REVIEW OF ANTICANCER THERAPY. 635-644.

DNA methylation: Its role in lung carcinogenesis and therapeutic implications.  EXPERT REVIEW OF ANTICANCER THERAPY. 667-679.

Combined modality therapy for limited-disease Small Cell Lung Cancer.  CURRENT TREATMENT OPTIONS IN ONCOLOGY. 69-74.

Lung cancer immunotherapy..  221-228.

Chemotherapy for advanced non-small-cell lung cancer..  173-178.